Jim Cramer answered viewers' Twitter from the floor of the New York Stock Exchange, commenting on Qorvo (QRVO), Celgene (CELG), Boston Scientific (BSX), and on why September is a tough month on Wall Street. A viewer asked about Qorvo. Cramer said the company had a disappointing quarter, which brought down other stocks including NXP Semiconductors (NXPI), which he likes better, and Skyworks Solutions (SWKS), which he says to buy in the 70s. Another viewer asked about a good entry point for Celgene (CELG), which Cramer said is a buy at $113 or below. Cramer was asked about his views on Boston Scientific (BSX), which he said is a good company, and that he likes the whole group, including CR Bard (BCR), Medtronic (MDT), Edwards Life Sciences (EW), and St. Jude Medical (STJ). Send your Twitter questions to @JimCramer using #CramerQ.
More from Video
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Real Money Video Wrap: Citi Surges as View of Stability Saves Sentiment
Citi overcame a mixed print to send its stock surging on Monday.
Real Money Video Wrap: Apple Rallies as Services Segment Takes Center Stage
There is a lot of Apple news to chew on Wednesday.
Are Algos Jumping on J&J Headlines?
Are machines jumping on Johnson & Johnson's human risk headlines?
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.